C4 Therapeutics Q3 2026 net loss narrows 32% year over year to $21.84 million
CCCC•C4 Therapeutics’ third-quarter 2026 net loss narrowed 32% year over year to $21.84 million, while revenue fell 25% to $8.47 million. The company reported $274.69 million in cash, cash equivalents and marketable securities at September 30, with funding expected through the end of 2028.
1. Quarterly results and outlook
C4 Therapeutics reported a third-quarter 2026 net loss of $21.84 million, down 32% year over year, and revenue of $8.47 million, down 25%. Cash, cash equivalents and marketable securities totaled $274.69 million at September 30, 2026, and the company expects funding through the end of 2028. Enrollment in the Phase 2 MOMENTUM trial remains on track to finish in the first quarter of 2027, with initial response data expected in the second half of 2027.
